Table 1.

Clinical outcomes of oral steroid method of preventing esophageal stricture after endoscopic resection.

Author, year	Design	Setting	Sample size (treated/control)	Follow-up	Stricture rate	Mean or median number of EBD	Adverse event
Lizuka, 2018 [25]	Retrospective cohort study	ESD 100% SEC	11/11	Gastroscopy: 1, 4, 8, 12, 16, and 20 weeks after ESD	36.4%VS 82% (P=0.04)	6.2 VS 19.4 (P=0.023)	8 VS 3 (P=0.043)
Zhou, 2017 [26]	Retrospective cohort study	ESD >75% ESCC	13/10	Gastroscopy: 1, 3, 6, and 12 months after ESD	23.1%VS 80% (P=0.007)	0.69 VS 13.5 (P=0.004)	None
Jean-Philippe,2017 [27]	Single-center retrospective study	EMR >50% Barrett's esophagus	29/0	Gastroscopy: 2, 6, 12, and 24 months after EMR	13%	2	None
Mikinori, 2015[23]	Retrospective cohort study	ESD >75% ESCC	17/16	Gastroscopy: 8 weeks after ESD	17. 6%VS 68.7% P<0.01	4.6 VS 8.1 P<0.01	None
Hiroki, 2013 [24]	Retrospective cohort study	ESD 100% SEC	10/13	Gastroscopy: 7 days, 2-, 3-, and 4-week interval until 9thweek after negative endoscopy	Both 100%	13.8 VS 33.5 P<0.001	None
Naoyuki, 2011 [28]	Case report	ESD 100% ESCC	1/0	Gastroscopy: 1, 3, and 6 months after ESD	0%	0	None
Hajime, 2011 [29]	Retrospective study	ESD 100% ESCC	4/3	Gastroscopy: 3, 6, and 12 months after ESD and then annually thereafter	Both 100%	3.25 VS 32.67 (P<0.05)	None
Naoyuki, 2011 [22]	Retrospective study	ESD >75% ESCC	19/22	Gastroscopy: 1, 3, 6, and 12 months after ESD and then annually thereafter	5.3%VS31.8% (P=0. 03)	1.7 VS 15.6 (P<0. 0001)	None

SEC, superficial esophageal cancer; ESCC, esophageal squamous cell carcinomas.